Navigation Links
Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B

LAGUNA NIGUEL, Calif., Oct. 3, 2011 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced that the European Medicines Agency (EMA) has validated and accepted the filing of the Marketing Authorization Application (MAA) for Inspiration's IB1001, a recombinant factor IX (FIX) product for the treatment and prevention of bleeding in individuals with hemophilia B.  In doing so, the EMA has verified that it will begin its regulatory review process of the MAA.

The application includes safety and efficacy data from Inspiration's clinical program for IB1001, which was conducted in the U.S., Europe, Israel and India.

Based on Inspiration's partnership agreement with the Ipsen Group (Euronext: IPN; ADR: IPSEY), which was signed in January 2010, by receiving the IB1001 MAA submission acceptance for review from the EMA, Inspiration will receive a $35 million milestone payment from Ipsen.  In return, Inspiration will issue a convertible note to Ipsen, bringing Ipsen's fully diluted equity ownership position in Inspiration to approximately 38%.

In late August, Ipsen and Inspiration extended their partnership to create a hemophilia business unit structure that will act as the exclusive sales organization for all hemophilia products commercialized under the Inspiration brand in Europe.

"The MAA submission for our lead program, IB1001, is Inspiration's first product approval regulatory filing, and a key step in the Company's transformation toward becoming a commercial-stage company," stated John Taylor, Co-Founder and Chairman of Inspiration.  "We believe the hemophilia community would like to see greater product choice. Currently, individuals with hemophilia B only have one marketed recombinant FIX treatment option.  Our IB1001 program is designed to increase product supply, provide patient choice, and help achieve our mission to broaden access to care worldwide."

About IB1001IB1001, Inspiration's lead product candidate, is an intravenous recombinant FIX product being developed for the treatment and prevention of bleeding in individuals with hemophilia B.  IB1001 has completed the pivotal Phase 3 clinical testing for the European regulatory submission, while clinical testing for the U.S. regulatory submission is ongoing.  To date, IB1001 has been well-tolerated by patients and pharmacokinetic results have demonstrated non-inferiority to the one approved recombinant FIX product currently available for the treatment of hemophilia B.

About Inspiration BiopharmaceuticalsInspiration Biopharmaceuticals is dedicated exclusively to developing treatments for hemophilia, with a primary mission to broaden access to care, including prophylactic therapy, and to improve the treatment of individuals with inhibitor complications.  Inspiration has a broad portfolio of recombinant hemophilia products, which includes two products in late-stage clinical development and two pre-clinical programs.

Inspiration's lead product candidates are IB1001, an intravenous recombinant factor IX (FIX) product for the treatment and prevention of bleeding in individuals with hemophilia B, and OBI-1, an intravenous recombinant porcine factor VIII (FVIII) product for the treatment of individuals with congenital hemophilia A who have developed inhibitors against human FVIII and for individuals with acquired hemophilia.  Both products are in advanced clinical development.  Earlier-stage preclinical programs at Inspiration are focused on human recombinant factor VIIa (FVIIa), for individuals with either hemophilia A or hemophilia B who have developed inhibitors, and for individuals with factor VII deficiency; and human recombinant FVIII, to treat individuals with hemophilia A.

Inspiration has extensive expertise and experience in hemophilia product development, biologics manufacturing, regulatory approval and global commercialization. The Company's senior leadership was directly responsible for the development and commercialization of the majority of hemophilia products currently on the market.  

In addition, in January 2010, Inspiration entered into a strategic partnership with the Ipsen Group, leveraging the combined expertise and resources of the two companies, to develop a broad portfolio of hemophilia products.  As announced in late August 2011, through an extension of the Company's existing partnership with Ipsen, Inspiration will be commercializing its hemophilia product portfolio in Europe, utilizing a hemophilia business unit structure being established within Ipsen's existing European commercial organization. For further information on Inspiration, please visit Contacts:Media

CompanyJustin Jackson

Mary BaumanMaroussia Czarny

Vice President, Global Commercial StrategyBurns McClellan

Email: mbauman@inspirationbio.comTel: +1-212-213-0006Email:

SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
2. Using magnetic toys as inspiration, researchers tease out structures of self-assembled clusters
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
4. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
5. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
6. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
7. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
8. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
9. Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
10. Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients
11. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
Post Your Comments:
(Date:10/8/2015)... 8, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, today announced its ... taking place in the month of October: ... RepliCel will be presenting at the annual Partnering ... Mesa to be held October 7-9 in ...
(Date:10/8/2015)... ... October 08, 2015 , ... ProMIS ... license agreement to develop and commercialize intellectual property rights belonging to The University ... February 2009, and affords exclusive worldwide rights to intellectual property based on use ...
(Date:10/7/2015)... ... 2015 , ... Neil Riordan, PhD to Discuss Medicinal Effects of Mesenchymal Stem ... from 3:50 pm to 4:30 pm. , Dr. Riordan is one of the early ... is the Co-Founder and Chief Science Officer of the Riordan-McKenna Institute of ...
(Date:10/7/2015)... N.Y. , Oct. 7, 2015   PDI ... today released an infographic that highlights key challenges across ... an appropriate disinfectant for the situation. This tool is ... steps hospitals can take to create efficiencies and lower ... The visual guide emphasizes examples of how to ...
Breaking Biology Technology:
... the people who helped North Carolina and Los Angeles ... communities of angel investors shared their most effective practices ... , ,Their techniques included educational programsbut you have to ... of the Council for Entrepreneurial Development , based ...
... Educating and advising potential angel investors, or cherubs, ... seraphs was the goal of a seminar at the ... titled Private Equity and Angel Investing Boot Camp, exposed ... resources and initiatives customized to help burgeoning investors make ...
... new leading security solution that combines networking infrastructure and ... approach to security. It is a logical step in ... imperatives from an IT perspective have been focused on ... components of network security. But more recently, with an ...
Cached Biology Technology:
(Date:9/8/2015)... 8, 2015  Affectiva, global leader in emotion-sensing ... Service, a new data solution, and version 2.0 ... Affectiva,s highly accurate and patented science, these new ... to transform industries such as market research, gaming, ... experience, online education, HR, automotive, robotics, healthcare and ...
(Date:9/2/2015)... 2, 2015 Security of data and ... banks, government organizations, telecommunications, hospitals, as well as ... previously being used to prevent unauthorised access. Technological ... wherein individuals could gain access to secure premises ... as hardware devices and numeric codes. However, hackers ...
(Date:9/1/2015)... MOUNTAIN VIEW, Calif. , Sept. 1, 2015 ... interaction with travelers during airport passenger screening. This ... which the passenger screening process will become unintrusive. ... and pre-clearance based on voluntary background investigations will ... analysis from Frost & Sullivan, Global Airport ...
Breaking Biology News(10 mins):
... one of the world,s largest and fastest growing open-access ... Frontiers in Bioengineering and Biotechnology . A ... Bioengineering and Biotechnology will provide a single open-access ... to be disseminated and discussed. Frontiers ...
... U.S. Forest Service scientists are part of "Landscapes ... the TKF Foundation, will examine how collaborative planning and ... from tragedy. , The TKF Foundation announced today that ... for grant funding. In addition to research on the ...
... have developed a novel technique that can detect molecular ... that is one of the most important, though time-consuming, ... a paper in Nature , post-doctoral researcher David ... Schnell of the Center for Free-Electron Laser Science (CFEL) ...
Cached Biology News:
... The 7500ce meets the demands of ... require high performance from reliable, robust and ... unmatched detection power in the most challenging ... It is equally suited to the toughest ...
... Certify products ATP-Free using Mo Bio ... sensitive ATP-Free certification service that will allow you ... level of accuracy and enable you to deliver ... Mo Bios ATP detection limit is 3.5 ...
... LC Sciences provides a comprehensive ... small regulatory/functional RNA embedded within non-coding ... technology and proprietary probe design, which ... detection of small RNAs (1). This ...
Best pricing for 100mg-1.0g scales. Phosphopeptides are our specialty....
Biology Products: